Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
EP2-R52H5 | Rat | Rat EphA2 Protein, His Tag (MALS verified) |
|
||
EP2-H82E4 | Human | Biotinylated Human EphA2 Protein, His,Avitag™ (MALS verified) |
|
Immobilized Biotinylated Human EphA2 Protein, His,Avitag (Cat. No. EP2-H82E4) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human Ephrin-A1, Fc Tag (Cat. No. EF1-H5251) with a linear range of 0.1-1 ng/mL (QC tested).
The purity of Rat EphA2 Protein, His Tag (Cat. No. EP2-R52H5) is more than 90% and the molecular weight of this protein is around 50-65 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Fallopian Tube Neoplasms; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Bone Neoplasms; Bile Duct Neoplasms; Thymoma; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Gastrinoma; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms; Somatostatinoma; Adenocarcinoma; Neoplasm Metastasis; Meningioma; Neoplasms; Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Carcinoid Tumor; Insulinoma; Carcinoma, Islet Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Sarcoma | Details |
Dasatinib Hydrate | NSC-732517; BMS-354825; XS-004 | Approved | Bristol-Myers Squibb Company | 施达赛, Dasynoc, Spricel, Sprycel, Spraysel | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Bristol-Myers Squibb Company | 2006-06-28 | Primary Myelofibrosis; Hemangiopericytoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Laryngeal Neoplasms; Lymphoma; Gliosarcoma; Peritoneal Neoplasms; Astrocytoma; Giant Cell Tumor of Bone; Gastrointestinal Stromal Tumors; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Chronic-Phase; Sarcoma, Ewing; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Sarcoma; Neurofibrosarcoma; Breast Neoplasms; Brain Neoplasms; Melanoma; Leukemia, T-Cell; Carcinoma, Hepatocellular; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Mycosis Fungoides; Heart Arrest; Mastocytosis; Tongue Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Uterine Neoplasms; Burkitt Lymphoma; Neoplasms, Gonadal Tissue; Intraocular Lymphoma; Lymphoma, Large-Cell, Anaplas | Details |
Regorafenib | DAST; BAY-73-4506 | Approved | Bayer AG | Stivarga, Resihance | United States | Colorectal Neoplasms | Bayer Healthcare Pharmaceuticals Inc | 2012-09-27 | Fallopian Tube Neoplasms; Osteosarcoma; Sarcoma, Ewing; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Bone Neoplasms; Bile Duct Neoplasms; Thymoma; Thyroid Neoplasms; Leukemia, Myeloid, Acute; Gastrinoma; Lung Neoplasms; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms; Somatostatinoma; Adenocarcinoma; Neoplasm Metastasis; Meningioma; Neoplasms; Solid tumours; Ovarian Neoplasms; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Carcinoid Tumor; Insulinoma; Carcinoma, Islet Cell; Stomach Neoplasms; Esophageal Neoplasms; Liver Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Pancreatic Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Adenoma; Glucagonoma; Carcinoma, Adenoid Cystic; Sarcoma | Details |
Dasatinib Hydrate | NSC-732517; BMS-354825; XS-004 | Approved | Bristol-Myers Squibb Company | 施达赛, Dasynoc, Spricel, Sprycel, Spraysel | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Bristol-Myers Squibb Company | 2006-06-28 | Primary Myelofibrosis; Hemangiopericytoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Laryngeal Neoplasms; Lymphoma; Gliosarcoma; Peritoneal Neoplasms; Astrocytoma; Giant Cell Tumor of Bone; Gastrointestinal Stromal Tumors; Sarcoma, Alveolar Soft Part; Leukemia, Myeloid, Chronic-Phase; Sarcoma, Ewing; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Sarcoma; Neurofibrosarcoma; Breast Neoplasms; Brain Neoplasms; Melanoma; Leukemia, T-Cell; Carcinoma, Hepatocellular; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Mycosis Fungoides; Heart Arrest; Mastocytosis; Tongue Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Uterine Neoplasms; Burkitt Lymphoma; Neoplasms, Gonadal Tissue; Intraocular Lymphoma; Lymphoma, Large-Cell, Anaplas | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
BT-5528 | BT-5528; BT5528 | Phase 2 Clinical | Bicycle Therapeutics | Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
siRNA-EphA2-DOPC | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms | Details | |
18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma | Details |
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) | Phase 1 Clinical | California Institute For Regenerative Medicine, National Cancer Institute | Glioblastoma | Details | |
BT-5528 | BT-5528; BT5528 | Phase 2 Clinical | Bicycle Therapeutics | Ovarian Neoplasms; Head and Neck Neoplasms; Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
siRNA-EphA2-DOPC | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Solid tumours; Ovarian Neoplasms; Pancreatic Neoplasms | Details | |
18F-Dasatinib | 18F-SKI-249380; [18F]-Fluoro-BMS-354825; [18F]Dasatinib; [18F]SKI-249380; [18F]Fluoro-BMS-354825 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Bone Marrow Neoplasms; Carcinoma; Neoplasms; Sarcoma; Diagnostic agents; Lymphoma; Melanoma | Details |
Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells therapy(California Institute For Regenerative Medicine) | Phase 1 Clinical | California Institute For Regenerative Medicine, National Cancer Institute | Glioblastoma | Details |
This web search service is supported by Google Inc.